Macular Edema

Research limited on role of combination therapy for CRVO-related MECombination therapy may be a reasonable approach to manage eyes that are not responding to intravitreal monotherapy with an anti-vascular endothelial growth factor (VEGF) agent or corticosteroid, said Lihteh Wu, MD, at the inaugural Retina World Congress.
New concepts about macular edema emerge from modern imaging studiesVolume-rendered optical coherence tomography (OCT) imaging allows new insight into retinal vascular flow and morphological changes in eyes with macular edema (ME), and the information obtained is the basis for new ideas about the pathogenesis of ME and therapeutic intervention, according to Richard F. Spaide, MD, Vitreous Retina Macula Consultants of New York.
DRCR.net retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Rescue alfibercept treatment proves successful for patients with BRVOPatients with branch retinal vein occlusion had better visual outcomes and decreased macular edema following intravitreal injection of aflibercept compared with laser treatment.
FDA expanded approval of aflibercept injection to treat diabetic retinopathyFDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema.
Anti-VEGF agent therapy rivals laser for macular edema in BRVOPatients treated with aflibercept intravitreal injections for macular edema associated with branch retinal vein occlusion had a significantly greater decrease in central retinal thickness and significantly greater improvement in vision compared with laser at the end of the 52-week VIBRANT trial.
Study suggests ranibizumab superior for edema secondary to BRVOHead-to-head randomized controlled study found ranibizumab to show more favorable results to treating macular edema secondary to BRVO than a single dose of dexamethasone.
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
Topical squalamine a promising treatment for RVO-induced ME
Topical squalamine a promising treatment for RVO-induced MEA proof-of-concept trial was launched to determine the safety and efficacy of squalamine lactate ophthalmic solution in eyes with macular edema secondary to branch and central retinal vein occlusion.
FDA approves Eylea for all forms of macular edema after retinal vein occlusionThe U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.